Apmonia Therapeutics
@ApmoniaTherap
Followers
20
Following
7
Media
2
Statuses
6
Apmonia Therapeutics is a biotechnology company developing a pipeline of targeted therapies for a solid cancers, based on specific and selective targets
Reims
Joined October 2022
📺Témoignage vidéo de la #startup @ApmoniaTherap qui se développe à #Reims ! Le #GrandReims, #territoire d'#innovation et d'#entrepreunariat doté d'un #écosystème adapté et d'une localisation stratégique ! #ReimsVisionR #TousLégendR à voir sur Linkedin 👇 https://t.co/VYwnymrPaJ
0
1
4
Apmonia Therapeutics and partners @GustaveRoussy and @CNRS will be presenting a poster at the 2023 @myESMO - European Society for Medical #Oncology #Gynecological #Cancers annual congress taking place 23-24 February in @barcelona_cat, Spain.
5
0
1
Come and meet our CEO Albin JEANNE next week in Strasbourg at @BIOFIT_EVENT, the European marketplace for deals in life sciences.
0
1
1
Bel article sur @ApmoniaTherap et sa technologie dans @LesEchos Merci @EYFrance pour cette mise en lumière Nice article presenting @ApmoniaTherap and the company's technology in @LesEchos Many thanks @EYFrance for this highlight https://t.co/7OtcSj1LcZ
#Cancer #oncology
lesechos.fr
Née de la recherche publique, la biotech rémoise développe un peptide, le TAX2, qui vise à empêcher la vascularisation des cellules cancéreuses. Les trois cofondateurs (Albin Jeanne, Stéphane Dedieu...
0
1
1
@ApmoniaTherap awarded “Scale-Up of the Year” (North of France) during @EYFrance Entrepreneur of the Year 30th ceremony This price rewards ground-breaking innovation and the considerable potential of ourtechnological platform for delivering new therapies #cancer #oncology
0
0
1
Apmonia Therapeutics announced in feb 2022 a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01) Portfolio of therapeutic #peptides targeting #tumor microenvironment in solid tumors https://t.co/pCd0GnpRa1
apmonia-therapeutics.com
 Apmonia Therapeutics announces a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01)  Success for Apmonia Therapeutics’...
0
0
0